Therapeutic use of Ligands for CD46 for treatment of patients with disorders associate patheogenetically w/inappropriate or excess production of IL-12.
The present invention provides a method of treating a variety of disorders in a mammal characterized by dysregulated, physiologically abnormal, aberrant IL-12 production and/or overproduction of IL-12. The mammal is preferably a human. As discussed herein, IL-12 is critical for the generation of cell mediated immune (CMI) responses, which in some instances are critical for clearance of and immunity to a wide variety of pathogens. Thus, the method of the invention is useful for the treatment of a variety of diseases in a mammal caused by pathogenic organisms. In addition, the method of the invention is usefull for the treatment of any other disease states which are associated with physiologically abnormal production, generally overproduction, of IL-12. Such diseases include those characterized by inappropriate CMI responses, and/or dysregulated type 1 cytokine expression, and/or pathological DTH responses. Patent (Set) 6,086,876Patents:
US 6,086,876
Inventor(s): Griffin, M. Diane E.
Type of Offer: Licensing
« More Pharmaceutical Patents